This gas station drug acts like opioids. It’s getting harder to buy
Hosted by Emily Kwong
- 14m
- Transcript
Summary
Written by a model from the transcript; not yet reviewed.
NPR science reporter Rachel Carlson joins hosts Emily Kwong and Regina Barber to examine the rise of Kratom and its derivative compound, 7OH, sold widely in gas stations and smoke shops. The guests and hosts explain how these products are marketed as energy boosts or pain relievers, yet bind to opioid receptors in the brain, leading to severe addiction and debilitating withdrawals for some users like Tyler and Brian, while others like Angela report relief from chronic conditions. The episode details a dramatic surge in poison control calls and deaths associated with mixed substances, explores the challenges of poor labeling and high costs, and outlines the DEA's emerging efforts to restrict concentrated synthetic derivatives.
- Products containing concentrated 7OH can be extremely addictive and cause severe flu-like withdrawal symptoms when stopped. 3:16
- Poison control calls related to Kratom have increased by 1,200 percent over a decade. 10:54
- The DEA has restricted certain lab-made opioid derivatives like MGM 15 and MGM 16 under the Controlled Substances Act. 13:49
Chapters
- 0:00Intro and Kratom Overview
Hosts introduce the episode and explain what Kratom is and its various forms.
- 0:53Tyler’s Journey from Opioid Withdrawal to 7OH
Rachel introduces Tyler, who used Kratom to ease opioid withdrawal and later tried 7OH tablets.
- 1:41The Potency and Addiction of 7OH
Tyler describes the powerful effects and addictive nature of 7OH tablets.
- 3:50Health Risks and Economic Costs
Experts explain withdrawal symptoms, high costs, and increased poison control calls linked to 7OH.
- 4:44Sponsor: Subaru
Subaru promotes its charitable event and vehicle sales.
- 5:54Other Users’ Experiences with 7OH
Stories of Brian and Angela illustrate both the addictive risks and therapeutic uses of 7OH.
- 9:25Regulatory Response and Future Restrictions
The conversation turns to DEA actions, potential bans, and the impact on users and industry lobbying.
- 15:19Wrap‑Up and Takeaways
Hosts summarize key points, thank Rachel, and provide resources for further listening.
- 15:55Sponsor: Breast Cancer Research Foundation
The foundation promotes awareness and donation opportunities.
Highlights
- 1:13
Using Kratom to Manage Opioid Withdrawalstory
Tyler explains how he started using ground-up Kratom leaves to help manage opioid addiction and stay off opioids for a decade.
- 1:57
Introduction of 7OH Tabletsdata
Tyler encountered 7OH tablets at a gas station, which provided strong euphoria similar to opioids because it binds to opioid receptors.
- 8:42
Managing Endometriosis Pain with 7OHstory
Angela Wilson shares that taking 30 to 40 milligrams of 7OH daily has been life-changing for managing her endometriosis pain and depression.
- 10:54
Spike in Poison Control Callsdata
Dr. Chris Holsteg discusses a recent report showing a 1,200% increase in poison control calls related to Kratom over the past decade.
- 12:52
Impractical Labeling and Dosinginsight
Rachel Carlson highlights the absurdity of dosing instructions on a 200-milligram tablet that would require cutting it into 26 tiny pieces.
- 13:49
DEA Federal Restrictionsstrategy
The DEA restricted the manufacture and sale of lab-made derivatives MGM 15 and MGM 16, classifying them alongside heroin and LSD.
Quotes
“He told me he thinks it did.”
Unnamed speaker · 1:41 “He said he thinks it helped him stop using opioids for a decade.”
Unnamed speaker · 1:42 “And that's partially because 7OH binds to opioid receptors in the brain.”
Unnamed speaker · 2:40 “I did not know at all what I was in for.”
Unnamed speaker · 2:53 “And he estimates he spent around $150 every single day on tablets.”
Unnamed speaker · 10:34 “This report he worked on included 233 deaths associated with Kratom between 2015 and 2025, but it didn't distinguish between Kratom and 7OH.”
Unnamed speaker · 11:10 “And the DEA says they plan to restrict 7OH alongside a different lab‑made opioid called metragenine pseudoindoxyl.”
Unnamed speaker · 14:13
Sponsored segments
- Edward Jones 4:10–4:43
- Subaru 4:44–5:07
- Dell Technologies 5:08–5:29
- Breast Cancer Research Foundation 15:55–16:09
- Capella University 16:10–16:23
About this episode
Support public media with NPR+ and enjoy perks for over 25 podcasts like this one. This show’s perks include sponsor-free listening. Learn more at plus.npr.org http://plus.npr.org/. See pcm.adswizz.com https://pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences. NPR Privacy Policy https://www.npr.org/about-npr/179878450/privacy-policy
Transcript
2,733 words · 8 speakers
Speaker names marked are inferred from speaking time and the show’s known hosts — they are not voice-verified.
Topics
- 7OH
- Kratom
- NPR
- Angie
- DEA
- Short Wave
- NIDA
- MGM 15
- MGM 16
- metragenine pseudoindoxyl
Page updated · transcript and summary are machine-generated